Ms. Hui Li | Oncology | Best Researcher Award

Ms. Hui Li’s research is focused on gastrointestinal oncology, with a particular emphasis on gastric and liver cancers. Her work is centered around exploring innovative therapeutic strategies, including targeting molecular pathways involved in tumor progression, metastasis, and drug resistance. One of her significant research areas is the application of multi-omics approaches to identify new biomarkers and therapeutic targets for gastrointestinal cancer. Additionally, Ms. Li has conducted studies on the efficacy of combination therapies, including the use of FADS2 inhibition alongside donafenib for hepatocellular carcinoma. Her research also delves into the role of autophagy and apoptosis in cancer cell survival, aiming to enhance the sensitivity of cancer cells to treatments like chemotherapy. Ms. Li’s research is contributing to the development of more effective, personalized cancer therapies that aim to improve survival rates and quality of life for patients diagnosed with gastrointestinal cancers.

Skills

Ms. Hui Li possesses a diverse set of skills that make her a proficient and innovative researcher in the field of oncology. She has strong laboratory skills in cell culture, gene editing, molecular biology techniques, and bioinformatics analysis, enabling her to conduct cutting-edge research in gastrointestinal cancer. Her experience in clinical data collection and analysis further enhances her ability to bridge the gap between laboratory findings and real-world medical applications. Ms. Li is also proficient in utilizing multi-omics approaches to identify novel therapeutic targets and biomarkers. Additionally, her expertise in statistical analysis and data interpretation allows her to draw meaningful conclusions from complex clinical datasets. Ms. Li’s collaborative nature and ability to communicate her findings clearly through publications and presentations demonstrate her capacity to work effectively in both independent and team-based research environments. Her ability to apply innovative approaches to cancer treatment makes her a valuable asset in the oncology research community.